Moreover, In prostate cancer, butyrate has also been shown to elevate circulating insulin-like growth factor-1 (IGF-1) levels, thereby activating the MAPK/PI3K pathway and promoting tumor progression 128. Here, IGF1 is linked to prostate carcinoma.